Nicotine, carcinogen, and toxin exposure in long-Term e-cigarette and nicotine replacement therapy users

Annals of Internal Medicine

Volumn 166, Issue 6, 2017, Pages 390-400

  Shahab, Lion ^a,b,c   Goniewicz, Maciej L ^a,b,c   Blount, Benjamin C ^a,b,c   Brown, Jamie ^a,b,c   McNeill, Ann ^a,b,c   Udeni Alwis, K ^a,b,c   Feng, June ^a,b,c   Wang, Lanqing ^a,b,c   West, Robert ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; ACROLEIN; ACRYLAMIDE; ACRYLONITRILE; BIOLOGICAL MARKER; CARCINOGEN; COTININE; ETHYLENE OXIDE; NICOTINE; NITROSAMINE; TOXIN; VOLATILE ORGANIC COMPOUND; C REACTIVE PROTEIN; CARBON MONOXIDE; NICOTINE GUM;

ADULT; ARTICLE; COMBUSTION; CROSS-SECTIONAL STUDY; ELECTRONIC CIGARETTE; ENGLAND; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SALIVA LEVEL; SMOKING; URINE LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; EDUCATIONAL STATUS; ETHNICITY; HAPPINESS; HIGH SCHOOL; LONG TERM EXPOSURE; MARRIAGE; PROTEIN BLOOD LEVEL; SALIVA; SINGLE (MARITAL STATUS); UNITED KINGDOM; URINE SAMPLING; WELLBEING; ADVERSE EFFECTS; CHEMISTRY; PROCEDURES; SALVIA; SMOKING CESSATION; TIME FACTOR; URINE;

ADULT; BIOMARKERS; CARCINOGENS; CROSS-SECTIONAL STUDIES; ELECTRONIC CIGARETTES; FEMALE; HUMANS; MALE; NICOTINE; NITROSAMINES; SALVIA; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; VOLATILE ORGANIC COMPOUNDS;

EID: 85017359616     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1107     Document Type: Article

References (70)

1. Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: A secondary analysis of 26 566 youth and adults from 27 Countries. Tob Control. 2015;24:442-8. doi:10.1136/tobaccocontrol-2013-051394
2. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109:1801-10. doi:10.1111/add.12659
3. Grana R, Benowitz N, Glantz SA. E-cigarettes: A scientific review. Circulation. 2014;129:1972-86. doi:10.1161 /CIRCULATIONAHA.114.007667
4. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133-9. doi:10.1136/tobaccocontrol-2012-050859
5. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols [Letter]. N Engl J Med. 2015; 372:392-4. doi:10.1056/NEJMc1413069
6. Kim HJ, Shin HS. Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatography-Tandem mass spectrometry. J Chromatogr A. 2013;1291:48-55. doi:10.1016/j.chroma.2013.03 .035
7. Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, et al. Exposure to electronic cigarettes impairs pulmonary antibacterial and anti-viral defenses in a mouse model. PLoS One. 2015; 10:e0116861. doi:10.1371/journal.pone.0116861
8. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98-103. doi:10.1136/tc.2009.031567
9. Etter JF, Bullen C, Flouris AD, Laugesen M, Eissenberg T. Electronic nicotine delivery systems: A research agenda. Tob Control. 2011;20:243-8. doi:10.1136/tc.2010.042168
10. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15: 267-70. doi:10.1093/ntr/ntr316
11. Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BW, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015;17:704-9. doi:10.1093/ntr/ntu218
12. McRobbie H, Phillips A, Goniewicz ML, Smith KM, Knight-West O, Przulj D, et al. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev Res (Phila). 2015;8:873-8. doi:10.1158/1940-6207.CAPR-15-0058
13. Goniewicz M, Gawron M, Smith DM, Peng M, Jacob III P, Benowitz N. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: A longitudinal withinsubjects observational study. Nicotine Tob Res. 2016. doi:10.1093/ntr/ntw160
14. Lee YH, Gawron M, Goniewicz ML. Changes in puffing behavior among smokers who switched from tobacco to electronic cigarettes. Addict Behav. 2015;48:1-4. doi:10.1016/j.addbeh .2015.04.003
15. McQueen A, Tower S, Sumner W. Interviews with "vapers": implications for future research with electronic cigarettes. Nicotine Tob Res. 2011;13:860-7. doi:10.1093/ntr/ntr088
16. Silla K, Beard E, Shahab L. Characterization of long-Term users of nicotine replacement therapy: evidence from a national survey. Nicotine Tob Res. 2014;16:1050-5. doi:10.1093 /ntr/ntu019
17. McMillen RC, Gottlieb MA, Shaefer RM, Winickoff JP, Klein JD. Trends in electronic cigarette use among U.S. adults: use is increasing in both smokers and nonsmokers. Nicotine Tob Res. 2015;17: 1195-202. doi:10.1093/ntr/ntu213.
18. Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev. 2011;30:119-23. doi: 10.1111/j.1465-3362.2010.00264.x
19. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res. 2009;11:1076-82. doi:10.1093/ntr /ntp104
20. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-Analysis. BMJ. 2009;338:b1024. doi:10.1136/bmj.b1024
21. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. doi:10.1002/14651858.CD000146.pub4
22. National Institute for Health and Care Excellence. Smoking: Harm Reduction. NICE Guideline no. PH45. London: National Institute for Health and Care Excellence; 2013. Accessed at www.nice .org.uk/guidance/ph45 on 12 August 2016.
23. Nelson VA, Goniewicz ML, Beard E, Brown J, Sheals K, West R, et al. Comparison of the characteristics of long-Term users of electronic cigarettes versus nicotine replacement therapy: A crosssectional survey of English ex-smokers and current smokers. Drug Alcohol Depend. 2015;153:300-5. doi:10.1016/j .drugalcdep.2015.05.005
24. Brose LS, Tombor I, Shahab L, West R. The effect of reducing the threshold for carbon monoxide validation of smoking abstinence-evidence from the English Stop Smoking Services. Addict Behav. 2013;38:2529-31. doi:10.1016/j.addbeh.2013.04 .006
25. Jacob P 3rd, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr. 1981;222:61-70.
26. Jacob P 3rd, Yu L, Wilson M, Benowitz NL. Selected ion monitoring method for determination of nicotine, cotinine and deuteriumlabeled analogs: Absence of an isotope effect in the clearance of (S)-nicotine-3', 3'-d2 in humans. Biol Mass Spectrom. 1991;20:247-252
27. McGuffey JE, Wei B, Bernert JT, Morrow JC, Xia B, Wang L, et al. Validation of a LC-MS/MS method for quantifying urinary nicotine, six nicotine metabolites and the minor tobacco alkaloids-Anatabine and anabasine-in smokers' urine. PLoS One. 2014;9:e101816. doi:10.1371/journal.pone.0101816
28. Wei B, Feng J, Rehmani IJ, Miller S, McGuffey JE, Blount BC, et al. A high-Throughput robotic sample preparation system and HPLC-MS/MS for measuring urinary anatabine, anabasine, nicotine and major nicotine metabolites. Clin Chim Acta. 2014;436:290-7. doi:10.1016/j.cca.2014.06.012
29. Xia B, Xia Y, Wong J, Nicodemus KJ, Xu M, Lee J, et al. Quantitative analysis of five tobacco-specific N-nitrosamines in urine by liquid chromatography-Atmospheric pressure ionization tandem mass spectrometry. Biomed Chromatogr. 2014;28:375-84. doi:10.1002/bmc.3031
30. Alwis KU, Blount BC, Britt AS, Patel D, Ashley DL. Simultaneous analysis of 28 urinary VOC metabolites using ultra high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (UPLC-ESI/MSMS). Anal Chim Acta. 2012;750: 152-60. doi:10.1016/j.aca.2012.04.009
31. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control. 2003;12:424-30.
32. Haussmann HJ. Use of hazard indices for a theoretical evaluation of cigarette smoke composition. Chem Res Toxicol. 2012;25:794-810. doi:10.1021/tx200536w
33. Burns DM, Dybing E, Gray N, Hecht S, Anderson C, Sanner T, et al. Mandated lowering of toxicants in cigarette smoke: A description of the World Health Organization TobReg proposal. Tob Control. 2008;17:132-41. doi:10.1136/tc.2007 .024158
34. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 83. Lyon, France: International Agency for Research on Cancer; 2004.
35. Smith CJ, Livingston SD, Doolittle DJ. An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke. Food Chem Toxicol. 1997;35:1107-30.
36. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-nitrosamines. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 89. Lyon, France: International Agency for Research on Cancer; 2007.
37. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91:1194-210.
38. International Agency for Research on Cancer. Dry cleaning, some chlorinated solvents and other industrial chemicals. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 63. Lyon, France: International Agency for Research on Cancer; 1995.
39. International Agency for Research on Cancer. Chemical agents and related occupations. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100F. Lyon, France: International Agency for Research on Cancer; 2012.
40. Shahab L, West R. Differences in happiness between smokers, ex-smokers and never smokers: cross-sectional findings from a national household survey. Drug Alcohol Depend. 2012;121:38-44. doi:10.1016/j.drugalcdep.2011.08.011
41. Ouellet-Morin I, Danese A, Williams B, Arseneault L. Validation of a high-sensitivity assay for C-reactive protein in human saliva. Brain Behav Immun. 2011;25:640-6. doi:10.1016/j.bbi .2010.12.020
42. Stepanov I, Sebero E, Wang R, Gao YT, Hecht SS, Yuan JM. Tobacco-specific N-nitrosamine exposures and cancer risk in the Shanghai Cohort Study: remarkable coherence with rat tumor sites. Int J Cancer. 2014;134:2278-83. doi:10.1002/ijc .28575
43. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59: 990-6.
44. Faul F, Erdfelder E, Lang AG, Buchner A. GPower 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-91.
45. O'Brien KM, Upson K, Cook NR, Weinberg CR. Environmental chemicals in urine and blood: improving methods for creatinine and lipid adjustment. Environ Health Perspect. 2016;124:220-7. doi:10.1289/ehp.1509693
46. Benjamini Y, Hochberg Y. Controlling the false discovery rate-A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289-300.
47. Hornung R, Reed L. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990; 5:46-51.
48. Dillon MC, Opris DC, Kopanczyk R, Lickliter J, Cornwell HN, Bridges EG, et al. Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels. Biomark Insights. 2010;5:57-61.
49. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77:145-58.
50. Fagerström KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control. 1997;6:311-6.
51. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl). 2014;231:401-7. doi:10.1007/s00213-013-3249-8
52. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133. doi:10.1038/srep04133
53. Shahab L, Dobbie F, Hiscock R, McNeill A, Bauld L. Prevalence and impact of long-Term use of nicotine replacement therapy in UK Stop-Smoking Services: findings from the ELONS study. Nicotine Tob Res. 2016. doi:10.1093/ntr/ntw258
54. Shahab L, Beard E, Brown J, West R. Prevalence of NRT use and associated nicotine intake in smokers, recent ex-smokers and longerterm ex-smokers. PLoS One. 2014;9:e113045. doi: 10.1371/journal.pone.0113045
55. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: A randomized controlled trial. Lancet. 2013;382:1629-37. doi:10 .1016/S0140-6736(13)61842-5
56. Rose JE, Salley A, Behm FM, Bates JE, Westman EC. Reinforcing effects of nicotine and non-nicotine components of cigarette smoke. Psychopharmacology (Berl). 2010;210:1-12. doi: 10.1007/s00213-010-1810-2
57. Shields PG. Long-Term nicotine replacement therapy: cancer risk in context. Cancer Prev Res (Phila). 2011;4:1719-23. doi:10.1158/1940-6207.CAPR-11-0453
58. Farsalinos KE, Gillman IG, Melvin MS, Paolantonio AR, Gardow WJ, Humphries KE, et al. Nicotine levels and presence of selected tobacco-derived toxins in tobacco flavoured electronic cigarette refill liquids. Int J Environ Res Public Health. 2015;12:3439-52. doi:10.3390/ijerph120403439
59. Schraufnagel DE, Blasi F, Drummond MB, Lam DC, Latif E, Rosen MJ, et al; Forum of International Respiratory Societies. Electronic cigarettes. A position statement of the forum of international respiratory societies. Am J Respir Crit Care Med. 2014;190:611-8. doi:10.1164/rccm.201407-1198PP
60. Kampa M, Castanas E. Human health effects of air pollution. Environ Pollut. 2008;151:362-7.
61. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: A systematic review. Ther Adv Drug Saf. 2014;5:67-86. doi:10 .1177/2042098614524430
62. McNeill A, Brose LS, Calder R, Hitchman S, Hajek P, McRobbie H. E-cigarettes: An Evidence Update. London: Public Health England; 2015.
63. Burstyn I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health. 2014;14:18. doi: 10.1186/1471-2458-14-18
64. Jacob P 3rd, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11:1668-73.
65. Jain RB. Distributions of selected urinary metabolites of volatile organic compounds by age, gender, race/ethnicity, and smoking status in a representative sample of U.S. adults. Environ Toxicol Pharmacol. 2015;40:471-9. doi:10.1016/j.etap.2015.07 .018
66. Stepanov I, Carmella SG, Briggs A, Hertsgaard L, Lindgren B, Hatsukami D, et al. Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res. 2009;69:8236-40. doi:10.1158 /0008-5472.CAN-09-1084
67. Weaver VM, Buckley T, Groopman JD. Lack of specificity of trans, trans-muconic acid as a benzene biomarker after ingestion of sorbic acid-preserved foods. Cancer Epidemiol Biomarkers Prev. 2000;9:749-55.
68. Cohen JT, Carlson G, Charnley G, Coggon D, Delzell E, Graham JD, et al. A comprehensive evaluation of the potential health risks associated with occupational and environmental exposure to styrene. J Toxicol Environ Health B Crit Rev. 2002;5:1-265.
69. Farsalinos KE, Voudris V, Poulas K. E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. Addiction. 2015;110: 1352-6. doi:10.1111/add.12942
70. Brown J, West R, Beard E, Michie S, Shahab L, McNeill A. Prevalence and characteristics of e-cigarette users in Great Britain: findings from a general population survey of smokers. Addict Behav. 2014;39:1120-5. doi:10.1016/j.addbeh.2014.03 .009